李斌，博士，暨南大学生命科学技术学院研究员、博士生导师，肿瘤分子生物学教育部重点实验室副主任，获暨南大学“双百英才”杰出人才称号。国家生命科学与技术人才培养基地（吉林大学/沈阳药科大学/中科院上海生物化学与细胞生物学研究所）获得本科和硕士学位，于2009年在香港大学生物医学学院获得博士学位。曾在国家人类基因组北方研究中心和香港大学分子生物学研究所工作，2009-2015年在香港大学医学院和癌症研究中心进行博士后研究。

     现研究方向：运用分子细胞生物学和蛋白质组学，研究肿瘤耐药、转移异质性及其与肿瘤微环境的相互作用和分子机制。近五年主持国家级科研项目4项，包括国家自然科学基金面上项目2项、国家自然科学基金香港联合项目1项、国家重点研发计划“蛋白质机器与生命过程调控”重点专项子课题1项，主持广东省自然科学基金、广州市科技计划项目、暨南大学跃升计划研究基金、香港大学基础研究基金等，与境外高校开展合作获批香港研究资助局项目，金额200多万港元。近5年以通讯或第一作者发表SCI论文30篇，总影响因子达200分，包括10分以上文章8篇、一区文章20篇，如Nature Communications、Advanced Science、Clinical Cancer Research、Signal Transduction and Targeted Therapy等。申请中国专利17项、已授权10项。应邀多次在美国、欧洲、澳洲、亚洲等国家和地区举行的国际会议上做学术报告，研究成果多次在国际国内会议上获奖，包括英国国家肿瘤年会奖、香港国际肿瘤会议最佳报告奖等。学术兼职包括香港大学医学院荣誉助理教授、中国抗癌协会肿瘤标志专业委员会青年委员、中国抗癌协会肿瘤标志专委会非编码RNA与肿瘤研究专委会委员、中国抗癌协会肿瘤标志专委会肿瘤标志物临床转化研究协作组委员、广东省抗癌协会肿瘤标志专委会委员、广东省抗癌协会肿瘤代谢专委会委员、广东省抗癌协会肿瘤转移专委会青年委员、广东省医学教育协会肿瘤学专委会委员等。担任Frontiers in Oncology等多个学术期刊编委，为Cancer Letters、Journal of Experimental and Clinical Cancer Research、Cancer Science、Frontiers in Oncology、Cancer Cell Int、Oncotarget等多个SCI期刊审稿人。

 2005-2009: 博士学位 香港大学医学院
 1997-2003: 本硕连读：国家生命科学与技术人才培养基地

                     吉林大学/沈阳药科大学/中科院上海生化所

2015–至今: 暨南大学 副研究员 研究员 博导
2009–2015: 香港大学生物医学学院、癌症研究中心 博士后
2004–2005: 香港大学分子生物学研究所 研究助理
2003–2004: 国家人类基因组北方研究中心 研究助理

五年内代表性文章（以通讯或第一作者发表，#共同第一，*共同通讯）:

1.Xu WW# * , Huang ZH#, Liao L, Zhang QH, Li JQ, Zheng CC, He Yan, Luo TT, Wang Y, Hu HF, Zuo Q, Chen WY, Yang QS, Zhao JF, Qin YR, Xu LY, Li EM, Liao HX, Li B*, He QY* (2020). Direct Targeting of CREB1 with Imperatorin Inhibits TGFβ2-ERK Signaling to Suppress Esophageal Cancer Metastasis. Advanced Science. 7(16):2000925. (一区, IF=15.8)

2.Xu WW#, Zheng CC#, Zuo Q, Li JQ, Hong P, Qin YR, Guan XY, He QY, Liao HX*, Li B*(2020). Genome-wide identification of key regulatory lncRNAs in esophageal cancer metastasis. Signal Transduction and Targed Therapy. Minor revision. (一区, IF=13.5)

3.Liao L#, Yao ZT#, Fang WK, He QY*, Xu WW*, Li B* (2020). Epigenetics in Esophageal Cancer: From Mechanisms to Therapeutics. Small Methods.4(10):202000391. (Review, IF=12.1)

4.Yang YM#, Hong P#, Xu WW*, He QY*, Li B* (2020). Advances in targeted therapy for esophageal cancer. Signal Transduction and Targed Therapy. 5:229. (Review, 一区, IF=13.5)

5.Hu HF, Xu WW, Zhang WX, Yan X, Li YJ, Li B*, He QY* (2020). Identification of miR-515-3p and its targets vimentin and MMP3 as a key regulatory mechanism in esophageal cancer metastasis: functional and clinical significance. Signal Transduction and Targed Therapy. 5:271. (一区, IF=13.5)

6.Hu HF, Xu WW, Li YJ, He Y, Zhang WX, Liao L, Zhang QH, Han L, Yin XF, Zhao XX, Pan YL, Li B*, He QY* (2020). Anti-allergic drug azelastine suppresses colon tumorigenesis by directly targeting ARF1 to inhibit IQGAP1-ERK-Drp1-mediated mitochondrial fission. Theranostics. doi:10.7150/thno.48698. (一区，IF=8.5)

7.Huang XH#, Yan X#, Zhang QH, Hong P, Zhang WX, Liu YP, Xu WW, Li B*, He QY* (2020). Direct targeting of HSP90 with daurisoline destabilizes β-catenin to suppress lung cancer tumorigenesis. Cancer Letters. 489:66-78. (一区, IF=7.4)

8.Hong P#, Liu QW#, Xie Y, Zhang QH, Liao L, He QY*, Li B*, Xu WW*. Echinatin suppresses esophageal cancer tumor growth and invasion through inducing AKT/mTOR-dependent autophagy and apoptosis (2020). Cell Death & Disease. 11(7):524. (二区, IF=6.3)

9.Wang Y, Zhang J, Li B*, He QY* (2019). Advance of proteomics on novel PTM discovery: the application in cancer therapy. Small Methods.3(5):1900041. (Review, IF=12.1)

10.Li B, Hong P, Zheng CC, Dai W, Chen WY, Yang QS, Han L, Tsao SW, Chan KT, Lee NPY, Law S, Xu LY, Li EM, Chan KW, Qin YR, Guan XY, Lung ML, He QY, Xu WW, Cheung AL (2019). Identification of miR-29c and its target FBXO31 as key regulatory mechanism in esophageal cancer chemoresistance-functional validation and clinical significance. Theranostics. 9(6):1599-1613. (一区，IF=8.5)

11.Yang J, Xu WW, Hong P, Ye F, Huang XH, Hu HF, Zhang QH, Yan X, Li B*, He QY* (2019). Adefovir dipivoxil sensitizes colon cancer cells to vemurafenib by disrupting the KCTD12-CDK1 interaction. Cancer Letters. 451:79-91.(一区, IF=7.4)

12.Zheng CC, Hu HF, Hong P, Yang J, Zhang QH, Xu WW, He QY*, Li B*(2019). Significance of integrin-linked kinase (ILK) in tumorigenesis and its potential implication as a biomarker and therapeutic target for human cancer. Am J Cancer Res.9(1):186-97. (Review, 二区, IF=5.2)

13.Huang XH, Wang Y, Hong P, Yang J, Zheng CC, Yin XF, Song WB, Xu WW, Li B*, He QY* (2019). Benzethonium chloride suppresses lung cancer tumorigenesis through inducing p38-mediated cyclin D1 degradation. Am J Cancer Res.9(11):2397-2412. (二区, IF=5.2)

14.Liu WT, Wang Y, Zhang J, Ye F, Huang XH, Li B*, He QY*. A novel strategy of integrated microarray analysis identifies CENPA, CDK1 and CDC20 as a cluster of diagnostic biomarkers in lung adenocarcinoma (2018). Cancer Letters. 425:43-53. (一区, IF=7.4)

15.Xu WW, Li B*, Zhao JF, Yang JG, Li JQ, Tsao SW, He QY, Cheung ALM*. IGF2 induces CD133 expression in esophageal cancer cells to promote cancer stemness (2018). Cancer Letters. 425:88-100. (一区, IF=7.4)

16.Yang J, Li B*, He QY*. Significance of prohibitin domain family in tumorigenesis and its implication in cancer diagnosis and treatment (2018). Cell Death & Disease. 9(6):580. (Review, 二区, IF=6.3)

17.Xu WW, Zheng CC, Huang Y, Chen WY, Yang QS, Ren JY, Wang YM, He QY, Liao HX*, Li B* (2018). Synephrine hydrochloride suppresses esophageal cancer tumor growth and metastatic potential through inhibition of Galectin-3-AKT/ERK signaling. J Agric Food Chem. 66(35):9248-58. (一区, IF=4.2)

18.Hu HF, Xu WW, Wang Y, Zheng CC, Zhang WX, Li B*, He QY* (2018). Comparative Proteomics Analysis Identifies Cdc42-Cdc42BPA Signaling as Prognostic Biomarker and Therapeutic Target for Colon Cancer Invasion. Journal of Proteome Research. 17(1):265-75. (二区, IF=4.1)

19.Wang Y, Li YJ, Huang XH, Zheng CC, Yin XF, Li B*, He QY* (2018). Liensinine perchlorate inhibits colorectal cancer tumorigenesis by inducing mitochondrial dysfunction and apoptosis. Food & Function. 9(11):5536-46. (一区, IF=4.2)

20.Xu WW#, Li B#, Guan XY, Chung SK, Wang Y, Yip YL, Law S, Chan KT, Lee PY, Chan KW, Xu LY, Li EM, Tsao SW, He QY*, Cheung AL* (2017). Cancer cell-secreted IGF2 instigates fibroblasts and bone marrow-derived vascular progenitor cells to promote cancer progression. Nature Communications.8:14399. (一区, IF=12.4)

21.Zhong Y, Yang J, Xu WW, Wang Y, Zheng CC, Li B*, He QY* (2017).KCTD12 promotes tumorigenesis by facilitating CDC25B/CDK1/Aurora A-dependent G2/M transition.Oncogene. 36(44):6177-89. (一区，IF=8.0)

22.Li B#, Xu WW#, Han L, Chan KT, Tsao SW, Lee NP, Law S, Xu LY, Li EM, Chan KW, Qin YR, Guan XY, He QY, Cheung AL (2017). microRNA-377 suppresses initiation and progression of esophageal cancer by inhibiting CD133 and VEGF. Oncogene.36(28):3986-4000.(一区, IF=8.0)

23.Li B, Xu WW, Lam AK, Wang Y, Hu HF, Guan XY, Qin YR, Saremi N, Tsao SW, He QY, Cheung AL (2017). Significance of PI3K/AKT signaling pathway in esophageal cancer metastasis and its potential as a target for anti-metastasis therapy. Oncotarget.8(24):38755-66.

24.Wang Y, Zhang J, Huang ZH, Huang XH, Zheng WB, Yin XF, Li YL, Li B*, He QY* (2017). Isodeoxyelephantopin induces protective autophagy in lung cancer cells via Nrf2-SQSTM1/p62-keap1 feedback loop. Cell Death & Disease. 8(6):e2876. (二区, IF=6.3)

25.Wang Y#, Yu RY#, Zhang J, Zhang WX, Huang ZH, Hu HF, Li YL, Li B*, He QY* (2017). Inhibition of Nrf2 enhances the anticancer effect of 6-O-angeloylenolin in lung adenocarcinoma. Biochemical Pharmacology. 129(12):43-53. (二区, IF=5.0)

26.Zheng WB, Li YJ, Wang Y, Yang J, Zheng CC, Huang XH, Li B*, He QY* (2017). Propafenone suppresses esophageal cancer proliferation through inducing mitochondrial dysfunction. Am J Cancer Res.7(11):2245-56. (二区, IF=5.2)

27.Wang Y, Zhang J, Li B*, He QY* (2017). Proteomic analysis of mitochondria: biological and clinical progresses in cancer. Expert Rev Proteomics.14(10):891-903. (Invited Review，IF=3.6)

28.Li B#, Xu WW#, Guan XY, Qin YR, Law S, Lee NP, Chan KT, Tam PY, Li YY, Chan KW, Yuen HF, Tsao SW, He QY, Cheung AL (2016). Competitive binding between Id1 and E2F1 to Cdc20 regulates E2F1 degradation and transcriptional activation of IGF2 to promote esophageal cancer chemoresistance. Clinical Cancer Research. 22(5):1243-55. (一区, IF=10.2)

29.Li J#, Li B#, Xu WW, Chan KW, Guan XY, Qin YR, Lee NP, Chan KT, Law S, Tsao SW, Cheung AL (2016). Role of AMPK signaling in mediating the anti-cancer effects of silibinin in esophageal squamous cell carcinoma. Expert Opinion on Therapeutic Targets. 20(1):7-18. (二区, IF=5.5)

30.Wang Y, Huang ZH, Li YJ, He GW, Yu RY, Yang J, Liu WT*, Li B*, He QY* (2016). Dynamic quantitative proteomics characterization of TNF-α-induced necroptosis. Apoptosis. 21(12):1438-1446. (二区, IF=4.5)

31.Li B, Tsao SW, Chan KW, Ludwig DL, Novosyadlyy R, Li YY, He QY, Cheung AL (2014). Id1-induced IGF2 and its autocrine/endocrine promotion of esophageal cancer growth and metastasis-Implications for IGF1R-targeted therapy. Clinical Cancer Research.20(10):2651-62. (一区, IF=10.2) (Featured Article in highlight of the issue, AACR Editor’s Picks, and MDLink)

1. P.I.: 国家自然科学基金面上项目，55万元, 2020-2023

2. P.I.: 国家自然科学基金与香港研究资助局联合项目，100万元，2020-2023

3. P.I.: 国家自然科学基金面上项目，60万元, 2018-2021

4. P.I.: 国家重点研发计划项目子课题，105万元/3124万元, 2017-2022

5. Co-I.: 香港研究资助局RGC项目，HK$1,166,553, 2018-2020
6. P.I.: 广州市科技项目，20万元, 2017-2019

7. P.I.: 广东省自然科学基金，10万元, 2016-2019

8. Co-I.: 香港研究资助局RGC项目，HK$1,081,941, 2016-2019

9. P.I.: 暨南大学科研培育与创新基金跃升计划，12万元，2017-2018

10. P.I.: 暨南大学高层次人才启动经费，50万元, 2015-2017
11. Co-I.: 国家自然科学基金面上项目,  74万元, 2015-2018
12. P.I.: 香港大学基础研究基金，HK$77,119, 2013-2014
13. P.I.: 香港大学基础研究基金， HK$56,457, 2011-2012

1.     普罗帕酮在制备治疗食管癌药物中的应用

2.     阿伏苯宗在制备抗肿瘤药物中的应用

3.     五氟利多在制备治疗食管癌药物中的应用

4.     一种检测结直肠癌中蛋白质组的方法

5.     盐酸氮卓斯汀在制备抑制结肠癌肿瘤生长药物中的应用

6.     欧前胡素在制备抑制食管癌肿瘤的药物中的应用

7.     莲心碱高氯酸盐在制备抗结直肠癌药物中的应用

8.     MEST作为新的肺癌临床生物标记物的应用

9.     一种食管癌的生物标志物及其应用

10.  苄索氯铵在制备用于防治肺癌的药物中的应用

1.香港大学生物医学学院荣誉助理教授

2.中国抗癌协会肿瘤标志专业委员会青年委员

3.中国抗癌协会肿瘤标志专委会非编码RNA与肿瘤研究专委会委员

4.中国抗癌协会肿瘤标志专委会肿瘤标志物临床转化研究协作组委员

5.广东省抗癌协会肿瘤标志专业委员会委员

6.广东省抗癌协会肿瘤代谢专业委员会委员

7.广东省抗癌协会肿瘤转移专业委员会青年委员

8.广东省医学教育协会肿瘤学专业委员会委员